M. Caniça has a degree in Pharmacy from the Fac. of Pharmacy, Univ. Lisbon, Portugal, and has the title of Specialist in Biochemical and Biological Sciences (BBS), by the Order of Pharmacists. The master's degree in 'Ecology and Pathogenesis of Microorganisms and Antimicrobial Agents' and the doctorate in 'Microbiology' were obtained at the University of Paris XI, France. She also has a master's degree in Microbiology, from the Fac. of Pharmacy and a PhD in 'Biomedical Sciences, specialty in Microbiology and Parasitology' from the Fac. of Medicine, both at Univ. Lisbon. Her Habilitation (eq. Aggregation) in Infectious Diseases was obtained in 2008, Portugal. GOVERNANCE / PROFESSIONAL AFFILIATIONS / RESEARCH AND PROFESSOR POSITIONS (most relevant): She has been Head of the National Reference Laboratory of Antibiotic Resistance and Healthcare-Associated Infections (NRL-AR/HAI), of the Reference/Health Surveillance Unit and from the Research & Development Unit, both from the Department of Infectious Diseases, from the National Institute of Health Dr. Ricardo Jorge (NIH), Lisbon. At the NRL, NIH, she has also been a group leader and senior researcher with the habilitation for scientific coordination in the area of antimicrobial resistance (AMR), mainly from bacteria isolated in human, but also animal and environmental reservoirs. At NIH she also served as President of the Scientific Council (2010-2017). She carried out as a University Professor, e.g. Associate Professor with Habilit./Agreg. at the Egas Moniz University Institute (IUEM), Portugal (2002-2020), where she was Director of the Postgraduate Course in BBS (2002-2016), and Director (2010-2016) and Co-Director ( 2016-2019) of the Master's Degree in BBS; she was also responsible for 4 curricular units, e.g. Molecular Microbiology. REFERENCE AND CONSULTANCY ACTIVITIES (some): In 2000, she joined the Meningococcal Diseases Group W135, of the Early Warning and Response System (EWRS)/G4 , at the European Commission; she was also part of the Network for Epidemiological Surveillance and Control of Communicable Diseases, in the EC, where, among others, she worked on the document: 'Council Recommendation/2002/77/EC on the prudent use of antimicrobial agents in human medicine'. She was national coordinator of the European AMR Surveillance System (EARSS) (1999-2009), and national coordinator of the Microbiological component of the European AMR Surveillance Network (EARS-Net) (2010-2013), currently operational contact point for AMR. She has been a member of the Scientific Board of the DGH National Program for the Prevention and Control of Infection and AMR (PPCIRA) and laboratory leader of this national AMR monitoring system (through NRL-AR/HAI, NIH). SCIENTIFIC ACTIVITIES (some): She is an integrated member and leader of the AMR Thematic Line of CECA-ICETA at Univ. Porto and collaborating member of CIISA (both FCT R&D Units), and integrated member of AL4AnimalS (Associated Lab, at Fac. Vet. Medicine, Univ. Lisbon). She was (co)director of MSc's and PhD students and author of >160 articles published in international peer-reviewed journals (e.g. Lancet Infect Dis, Nat Microbiol, Euro Surveill, PNAS, AAC, JAC, IJAA, EID, CVI, STOTEN, Front Microbiol, Environ Microbiol, Microbiol Spectr). She is/was a partner and coordinator in Portugal of European projects, Co-PI in an EU project, PI at national level e.g. in FCT and industry projects, collaborator or consultant e.g. in FCT projects. FIELD OF R&D: She focuses mainly on the mechanisms responsible for AMR in bacteria of clinical origin but, taking into account the current scenario, she has also approached this area from a One Health (OH) perspective. To this end she uses different approaches, e.g. genomics and metagenomics, and their respective analysis. IMPACT OF R&D: She considers a privilege to carry out research in the area of AMR, with results having important scientific, economic/technological and/or social impacts.